Eli Lilly has to wait a while longer for FDA verdict

Partners Eli Lilly and Incyte will have to wait until Q3 to find out whether the US health authorities can approve their drug Oluminant as a treatment for atopic dermatitis.


Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

WS Audiology plans to list subsidiary

Privately-owned hearing aid company WS Audiology, which grew out of the merger between Widex and Sivantos, plans to list, which handles online sales.

Further reading

Related articles

Latest news

See all jobs